Kati Waldenburg

MD overseeing public relations at CORE PR

[CoreIR @CoreIR_]

CORE IR announces the expansion of its Healthcare Communications and Investor Relations Practice, significantly enhancing the company's ability to provide best-in-class strategic counsel to publicly traded and private healthcare companies.

Read more: https://t.co/hzCPgysB87

[CoreIR @CoreIR_]

Happy National Pet Month from @CoreIR_! We’re celebrating the furry companions who brighten our days and make the very best office sidekicks.

[CoreIR @CoreIR_]

Our team had a fantastic time with @CoreIR_ client @RichtechRobots at @seeyou_tmrw in Times Square! We saw ADAM in action, even serving @SHAQ a cup of coffee!

[Plus Therapeutics (Nasdaq: PSTV) @plustxinc]

$PSTV's CEO and President, Dr. Marc Hedrick, joined @MicheleSteele on @Stocktwits @ST_BoardroomX series to discuss recent momentum across the company, including the @US_FDA Orphan Drug Designation for REYOBIQ™ in pediatric brain cancer, expanded payer coverage and an AMA PLA code for CNSide®, and what these milestones mean for the path toward commercialization.

Watch here: https://t.co/jzlUOtIkTH

@CNSideDx

[CoreIR @CoreIR_]

What does successful IR look like? At #COREIR, it’s strategic support that drives visibility and market engagement. Our services include investor engagement, integrated communications, capital markets advisory, and ongoing program management.

Learn more: https://t.co/k0J5jLEOCR

[Kati Waldenburg @KatiPR05]

@PolaryxTx @NasdaqExchange @WORLDSymposia Congratulations on all the milestones!

[CoreIR @CoreIR_]

Experience the difference with @CoreIR_.

#COREIR delivers strategic #IR and #PR support backed by deep market expertise and a commitment to client success.

Explore more: https://t.co/QxdQ5FnU6X

#COREPR #IR #PR

[Nasdaq Exchange @NasdaqExchange]

Welcoming @PolaryxTx [PLYX] to the
@NasdaqExchange Closing Bell in celebration of their recent listing.
https://t.co/F3Ojiq4tWz

[Polaryx Therapeutics @PolaryxTx]

#PolaryxTherapeutics announces that shares of the Company’s common stock have been approved for listing on the @Nasdaq Capital Market under the ticker symbol $PLYX. Shares are expected to commence trading on or about February 2, 2026.

Read more: https://t.co/eGIV0KMStT

#Nasdaq

[Polaryx Therapeutics @PolaryxTx]

#Polaryx is working to deliver treatments for #lysosomalstoragedisorder patients. Our multi-modal pipeline includes small molecule therapies that aim to promote lysosome biogenesis via PPARα-dependent TFEB upregulation, attenuate neuroinflammation, & enhance neuronal survival.

Learn more: https://t.co/SqBT5TcJcJ

[CoreIR @CoreIR_]

The #COREIR team is excited to attend the Annual @jpmorgan Healthcare Conference alongside many of our clients at this premier healthcare investment event.

See you there!

#JPM2026

[CoreIR @CoreIR_]

#COREIR's President and Co-Founder, Scott Gordon, shared insights with @commPRObiz on how New Year’s resolution marketing is shifting heading into 2026, with credibility and proven performance taking priority.

Read the full article: https://t.co/EOJPQs77r7

#EmployeeInsights

[CoreIR @CoreIR_]

The @CoreIR_ team wishes everyone happy holidays!

Here’s to a joyful season filled with celebration and good company.

[CoreIR @CoreIR_]

A great night with some of the #COREIR team celebrating a year of collaboration and momentum.

Looking ahead to an exciting year!

#CompanyCulture

[Plus Therapeutics (Nasdaq: PSTV) @plustxinc]

$PSTV's encouraging data presented at @SABCSSanAntonio represents a meaningful step forward in leptomeningeal metastases treatment options.

Dr. Andrew Brenner, dives into the key takeaways from #PSTV’s #SABCS25 presentations with @AJMC_Journal in this video interview: https://t.co/iz09YJdtiG

#ClinicalTrial #BreastCancer #Radiotherapeutic #ClinicalTrials #LeptomeningealMetastases #SABCS

[CoreIR @CoreIR_]

Companies partner with @CoreIR_ to drive capital formation, #investorgrowth, and market visibility.

From investment theses to press releases, social media, earnings calls, and more, we ensure your message is delivered and understood.

Learn more: https://t.co/QxdQ5ForWv
#COREIR

[CoreIR @CoreIR_]

Today, influence and trust matter more than ever.

#ThoughtLeadership helps executives and teams shape conversations and build credibility.

Read how to amplify your voice and stand out in this edition of #IntheCORE: https://t.co/7Su3TEHCsy

#COREIR #COREPR #COREDigital

[Plus Therapeutics (Nasdaq: PSTV) @plustxinc]

$PSTV's CEO, Marc Hedrick, M.D., was featured as a key opinion leader in a recent @Nature Cancer article discussing how companies are advancing next-generation #radiopharma treatments ahead of major data readouts.

“Plus Therapeutics is using rhenium-186, whose 90-hour half-life and 2- to 4-mm beta-radiation pathlength, plus gamma imaging rays, appear ideal for central nervous system cancers including invasive glioblastomas and leptomeningeal metastases, which can be diffuse and tricky to image...The nature of rhenium-186 radiation — with a longer path length than that of alpha emitters, but higher energy than the slower-decaying beta emitter lutetium — may help to overcome brain tissue’s high radioresistance.”

Read the article here: https://t.co/Bwcef7IE03

More about the #radiotherapeutics: https://t.co/tuWsoWuRZy

[Plus Therapeutics (Nasdaq: PSTV) @plustxinc]

#PlusTherapeutics' President and CEO, Marc Hedrick, M.D., traveled to the @NasdaqExchange to speak with @RemyBlaireNews of @FintechTvGlobal to discuss @UHC's National Coverage Agreement of @CNSideDx's Cerebrospinal Fluid Assay for #leptomeningealmetastases.

Check out the interview below and additional #PSTV video content on our @YouTube page: https://t.co/XERIjtYrPE

#LeptomeningealCancer #PSTV #CNSide $PSTV @Nasdaq

[KairosPharma @KairosPharma]

$KAPA will host a KOL event next Thursday to discuss interim efficacy results from its Phase 2 #clinicaltrial of #ENV105 for advanced #prostatecancer.

Register here: https://t.co/PH0FdJldoP

PR here: https://t.co/Ggyp6aJwLr

@huntsmancancer @massgeneralnews @harvardmeded #KAPA